other_material
confidence high
sentiment positive
materiality 0.65
Phio signs cGMP manufacturing deal; PH-762 Phase 1b shows 85% pathological response
Phio Pharmaceuticals Corp.
- Entered cGMP drug product manufacturing agreement with U.S. manufacturer for clinical and commercial supply of PH-762.
- PH-762 Phase 1b trial: 22 patients completed, no dose-limiting toxicities or serious adverse events.
- Pathological response rate across all cohorts ~65%; highest-dose cohort achieved 85% (6 of 7 patients).
- FDA engagement for next-stage clinical development targeted for Q2 2026.
- Cash and equivalents projected to sustain operations into H1 2027.
item 8.01